Providing funding for the DEA above the FY26 enacted level to curb the flow of China’s illicit export of fentanyl and fentanyl precursors into America.
Provide funding for the DEA above the FY26 enacted level to curb the flow of fentanyl and fentanyl precursors into the United States.
Occurrences
Evidence
The House Appropriations Committee approved the FY27 CJS bill on May 13, 2026. The committee release says the bill provides funding above the FY26 enacted level for the Drug Enforcement Administration and increases funding for DEA to combat fentanyl and its precursors from China.
On May 14, 2026, Díaz-Balart said the committee-approved FY27 CJS bill provides funding for the DEA above the FY26 enacted level to curb the flow of China's illicit export of fentanyl and fentanyl precursors into America.
The FY26 enacted CJS summary says DEA received a direct appropriation of $3.250 billion and notes that the bill increases funding for the Drug Enforcement Administration by $63 million to end the scourge of fentanyl and other illicit drugs.
Assessments
The evidence shows Diaz-Balart and the House Appropriations Committee advanced an FY27 CJS appropriations bill that would fund the DEA above the FY26 enacted level and explicitly ties the increase to fentanyl and precursor interdiction. However, committee approval is not enacted funding, so the promised spending outcome has not yet been delivered. Because the appropriations process appears pending rather than finally failed, the status is unresolved, with an effort badge for materially advancing the proposal in the same federal term.